4-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylate potassium salt | 954125-12-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylate potassium salt
• 英文别名: potassium;4-chloro-1-(2-trimethylsilylethoxymethyl)imidazole-2-carboxylate
• CAS: 954125-12-3
• 化学式: C₁₀H₁₆ClN₂O₃Si*K
• 分子量: 314.885
• InChiKey: BLOBACXYGINPKB-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  -1.78
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  67.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6'-(2,6-diethyl-1,1-dioxo-1lambda6-[1,2,6]thiadiazinan-4-yl)-4-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-ylamine 、 4-chloro-1-(2-trimethylsilanyl-ethoxymethyl)-1H-imidazole-2-carboxylate potassium salt 生成 4-Chloro-1H-imidazole-2-carboxylic acid [6'-(2,6-diethyl-1,1-dioxo-1lambda6-[1,2,6]thiadiazinan-4-yl)-4-methyl-3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-3'-yl]-amide
  参考文献：
  名称：

  INHIBITORS OF C-FMS KINASE

  摘要：

  本发明涉及式I的化合物：其中Z，X，J，R2和W在规范中列出，以及其溶剂化物，水合物，互变异构体和药学上可接受的盐，可以抑制蛋白酪氨酸激酶，特别是c-fms激酶。还提供了使用式I的化合物治疗自身免疫性疾病和具有炎症成分的疾病；治疗卵巢癌，子宫癌，乳腺癌，前列腺癌，肺癌，结肠癌，胃癌，毛细胞白血病的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或内脏，炎症和神经性疼痛；以及骨质疏松症，Paget病和其他骨吸收介导的疾病，包括类风湿性关节炎和其他形式的炎症性关节炎，骨关节炎，假体失效，骨溶性肉瘤，骨髓瘤和转移至骨骼的肿瘤。

  公开号：

  US20070249593A1

文献信息

• Inhibitors of C-FMS kinase
  申请人：Illig Carl R.

  公开号：US08674100B2

  公开（公告）日：2014-03-18

  The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are as set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. The compounds of formula I are useful for treating a variety of disorders including autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and psoriasis.

  本发明涉及I式化合物：其中Z，X，J，R2和W如规范所述，以及其溶剂化物，水合物，互变异构体和药学上可接受的盐，该化合物抑制蛋白酪氨酸激酶，特别是c-fms激酶。I式化合物对于治疗多种疾病包括自身免疫性疾病如类风湿性关节炎，多发性硬化症和牛皮癣等非常有用。
• Inhibitors of c-fms kinase
  申请人：Janssen Pharmaceutica NV

  公开号：US09221797B2

  公开（公告）日：2015-12-29

  The invention is directed to compounds of Formula I: wherein Z, X, J, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula I, are also provided.

  本发明涉及式I的化合物：其中Z、X、J、R2和W在规范中说明，以及其溶剂化物、水合物、互变异构体和药学上可接受的盐，该化合物抑制蛋白酪氨酸激酶，特别是c-fms激酶。本发明还提供了使用式I的化合物治疗自身免疫性疾病和具有炎症成分的疾病；治疗卵巢癌、子宫癌、乳腺癌、结肠癌、胃癌、毛细胞白血病和非小细胞肺癌的转移；以及治疗疼痛，包括肿瘤转移或骨关节炎引起的骨骼疼痛，或者内脏、炎症和神经源性疼痛；以及骨质疏松症、帕吉特病和其他骨吸收介导的疾病，包括关节炎、假体失效、骨溶性肉瘤、骨髓瘤和转移至骨骼的肿瘤。